KR102877057B1 - A dermal filler composition - Google Patents

Abstract

The dermal filler composition of the present disclosure comprises a carotenoid.

Description

{A DERMAL FILLER COMPOSITION}

The present disclosure relates to a dermal filler composition that is injected into a skin layer of a human body, and more specifically, to a dermal filler composition that implements a color similar to the color of human fat.

Among dermal fillers, hyaluronic acid fillers are used in cosmetic procedures to add volume to the skin and improve wrinkles. Hyaluronic acid, a naturally occurring substance in the human body, has excellent water-attracting and retention abilities, providing natural volume and hydration to keep skin smooth.

However, when hyaluronic acid fillers are injected into thin skin layers (such as the forehead, bridge of the nose, and under the eyes), there is a risk of the Tyndall effect. This phenomenon occurs when light passes through the injected area, causing the filler to appear blue or bluish. This Tyndall effect can result in cosmetically unsatisfactory results and can be a concern for post-procedure appearance.

The aforementioned issues are limitations of fillers. To address this issue, fat grafting can be performed instead of injecting fillers into the affected skin layer. Fat grafting requires harvesting fat from the donor site, which can result in scarring and requires a long recovery period. Furthermore, the degree of graft engraftment is difficult to predict, requiring multiple liposuction sessions or, if the volume exceeds expectations, repeated liposuction. This complicates and complicates the process.

The present disclosure seeks to solve the above-mentioned problems.

Specifically, one of the problems that the present disclosure seeks to solve is to provide a dermal filler composition implemented with a color similar to the color of fat to improve the aforementioned tindling phenomenon.

Additionally, one of the problems that the present disclosure seeks to solve is to provide a dermal filler composition that helps in tissue repair and regeneration in a skin layer into which the filler is injected.

To achieve the aforementioned purpose, a dermal filler composition containing a carotenoid is provided.

In an exemplary embodiment, the carotenoids are characterized as being β-carotene.

In an exemplary embodiment, the weight ratio of the carotenoids is characterized by being 3 μg to 60 μg per 1 g of the dermal filler composition.

In an exemplary embodiment, the carotenoids are characterized by being formed from a first combination comprising at least one of β-carotene, α-carotene, lycopene, β-cryptoxanthin, lutein, zeaxanthin, saffron yellow, and alpha crocin.

In an exemplary embodiment, the weight ratio of the first combination is characterized by being 3 μg to 60 μg per 1 g of the dermal filler composition.

In an exemplary embodiment, the dermal filler composition is characterized by further comprising hyaluronic acid, a cross-linking agent, and a buffer.

In an exemplary embodiment, in the dermal filler composition, the hyaluronic acid accounts for a weight ratio of 0.01 g to 0.03 g per 1 g of the dermal filler composition, the cross-linking agent accounts for a weight ratio of 0.005 g to 0.025 g per 1 g of the dermal filler composition, and the buffer accounts for the remaining weight ratio excluding the carotenoids, the hyaluronic acid, and the cross-linking agent.

In an exemplary embodiment, the dermal filler composition is characterized in that it further comprises lidocaine.

In an exemplary embodiment, the wavelength of visible light reflected by the filler composition is characterized as being 570 nm to 610 nm.

In an exemplary embodiment, the hue value of the filler composition is characterized by being 15 to 60 degrees.

In an exemplary embodiment, the filler composition is characterized in that it is used by being injected into the forehead, under the eyes, and bridge of the nose among the skin layers of a human body.

The dermal filler composition of the present disclosure may include a yellow or orange colored carotenoids, so that the dermal filler composition may resemble the color of fat and improve the Tyndall phenomenon.

In addition, since the dermal filler composition of the present disclosure may include a carotenoid that performs antioxidant and immune activating actions, the dermal filler composition may help in tissue repair and regeneration of the skin layer into which the filler is injected.

Figure 1 is a photograph of samples of fat extracted from a human body.
Figure 2 is a photograph showing the color tone values of fat extracted from the human body.
Figure 3 is a diagram showing the wavelength of visible light corresponding to the color tone value.

Hereinafter, preferred embodiments of the present disclosure will be described in detail with reference to the attached drawings. The advantages and features of the present disclosure, and methods for achieving them, will become clearer with reference to the embodiments described in detail below together with the attached drawings. However, the technical idea of the present disclosure is not limited to the following embodiments and may be implemented in various different forms. The following embodiments are provided only to complete the technical idea of the present disclosure and to fully inform those skilled in the art of the present disclosure of the scope of the present disclosure, and the technical idea of the present disclosure is defined only by the scope of the claims.

When assigning reference numerals to components in each drawing, it should be noted that identical components are assigned the same numerals whenever possible, even if they appear on different drawings. Furthermore, when describing the present disclosure, if a detailed description of a related known configuration or function is deemed likely to obscure the gist of the present disclosure, such detailed description will be omitted.

Unless otherwise defined, all terms (including technical and scientific terms) used herein may be used in the same sense as commonly understood by those of ordinary skill in the art to which this disclosure pertains. Furthermore, terms defined in commonly used dictionaries are not to be interpreted ideally or excessively unless explicitly and specifically defined otherwise. The terminology used herein is for the purpose of describing embodiments and is not intended to limit the disclosure. In this specification, singular forms also include plural forms, unless specifically stated otherwise.

Additionally, terms such as first, second, A, B, (a), (b), etc. may be used to describe components of the present disclosure. These terms are only intended to distinguish the components from other components, and the nature, order, or sequence of the components are not limited by the terms. When a component is described as being "connected," "coupled," or "connected" to another component, it should be understood that the component may be directly connected or connected to the other component, but another component may also be "connected," "coupled," or "connected" between each component.

As used herein, the terms “comprises” and/or “comprising” do not exclude the presence or addition of one or more other components, steps, operations and/or elements.

Components included in one embodiment and components with common functions may be described using the same designations in other embodiments. Unless otherwise stated, the descriptions provided in one embodiment may also apply to other embodiments, and specific descriptions may be omitted to the extent that they overlap or would be readily apparent to those skilled in the art.

Hereinafter, the technical idea of the present disclosure will be described in detail with reference to preferred embodiments of the present disclosure and the attached drawings.

The dermal filler composition of the present disclosure may be a filler composition that implements a color similar to the color of human fat and is injected into the skin layer of the human body. Specifically, the dermal filler composition of the present disclosure is a filler composition comprising hyaluronic acid, and may be configured to implement a color similar to the color of fat to suppress the Tyndall phenomenon when injected into the skin layer.

In general, the color of fat tends to be similar across races. For example, while skin colors may vary between Asians, Westerners, and Africans, the color of fat remains substantially similar. Adipose tissue in the human body is generally known to have a yellow or orange hue, a result of carotenoids (or carotenoid pigments) present within the fat. Adipose tissue, a major energy storage substance, accounts for a relatively large proportion of fat cells and exhibits a similar color across most people, regardless of race.

The dermal filler composition of the present disclosure may further include a carotenoid in the hyaluronic acid (HA) filler to achieve a color similar to that of fat. Since the dermal filler composition can achieve a yellow color similar to fat, the filler injection site can appear natural (i.e., not transparent) after the procedure. This can reduce the Tyndall effect, which occurs when filler is injected into areas with thin skin, thereby contributing to improved cosmetic results after the procedure.

Specifically, the dermal filler composition of the present disclosure can be injected into thin skin layers of the human body (e.g., the forehead, bridge of the nose, and under the eyes). However, the present disclosure is not limited thereto, and the dermal filler composition can also be injected into relatively thin skin layers in various parts of the human body. Since the dermal filler composition of the present disclosure can implement a color similar to fat, the phenomenon of light passing through the area into which the filler of the present disclosure is injected being discolored to blue or bluish can be reduced. Accordingly, the dermal filler composition of the present disclosure can provide cosmetic satisfaction and reduce the stress of the practitioner due to appearance problems after the procedure.

Furthermore, when the dermal filler composition of the present disclosure is injected into a dermal layer, the carotenoids contained in the dermal filler composition of the present disclosure can gradually transition to an active state over time. At this time, the activated carotenoids can exert beneficial physiological effects, such as antioxidant activity and immune activation, beyond the aforementioned cosmetic effects. These antioxidant and immune activation effects can occur freely over time as the filler is absorbed and decomposed in the body, and can assist in tissue repair and regeneration in the injected dermal layer.

Activated carotenoids can prevent cell damage through antioxidant action until the filler is absorbed, and can promote the recovery of surrounding tissues by activating the immune system. Because the dermal filler composition of the present disclosure includes carotenoids, the dermal filler composition of the present disclosure can provide both cosmetic benefits (inhibiting the Tyndall phenomenon) and physiological benefits.

Below, the components included in the filler composition of the present disclosure are specifically described.

The filler composition of the present disclosure may be a filler composition comprising a carotenoids added to a hyaluronic acid filler. To enable the filler composition of the present disclosure to have a color similar to that of human fat, the applicant first analyzed the color of human fat and changed the color of the filler composition based on the analyzed results.

Figure 1 is a photograph of samples of fat extracted from a human body. Figure 2 is also a photograph showing the color tone values of fat extracted from a human body.

Referring to Figure 1, the applicant extracted 100 human fat samples from 100 people. In other words, the applicant extracted fat from the bodies of 100 different people. Furthermore, referring to Figure 2, the applicant obtained the hue values (hue values) of the 100 extracted fat samples, and also obtained the numerical range of the hue values of the fat samples.

The above hue value is a color expression method that represents a color, and may be a value that represents a color as an angle on a circular color wheel. Specifically, the hue value (Hue value) can have a range from 0 degrees to 360 degrees, and the color can change depending on this angle. For example, 0 degrees can represent red, 120 degrees can represent green, and 240 degrees can represent blue. In other words, the hue value (Hue value) is a value that expresses a color numerically (i.e., an angle), and through this, the type of color can be described.

The color tone value of human body fat can be obtained by a color measurement device that detects light reflected from a fat sample, converts it into an RGB value, and then derives a color tone value (Hue value) on a color wheel based on this value. In other words, the color measurement device can precisely analyze the degree of color tone of the fat color.

First, a step of shining light on the fat sample to obtain RGB values from the fat sample and detecting the reflected light by a color measuring device, and a step of extracting RGB values by the color measuring device can be performed.

Each of the 100 fat samples can reflect the light provided, and the intensity of said light can be detected by a color measuring device by dividing it into the intensities of red (R), green (G), and blue (B). That is, the color measuring device can calculate the RGB value by measuring how strongly the intensity of light reflected from the fat sample is reflected for each color (R, G, B).

After RGB values are calculated from a fat sample, the RGB color information can be converted to HSV (hue, saturation, value) or HSB (hue, saturation, brightness) information to derive the hue value of the fat sample. By converting the RGB values to HSV or HSV values, the position of the yellow light in the fat sample on the color wheel can be clearly identified.

Specifically, first, a step of normalizing the RGB values extracted from the fat sample can be performed. Since RGB values range from 0 to 255, a step of dividing the R, G, and B values by 255 can be performed. For example, if the RBG values are (230, 195, 60), the normalized values can be (0.902, 0.765, 0.235).

Second, the largest and smallest values can be extracted from the normalized RGB values. These extracted values can be used to calculate the hue value. For example, if the normalized values are (0.902, 0.765, 0.235), the largest value (Max value) could be 0.902, and the smallest value (Min value) could be 0.235.

Thirdly, the Hue value can be calculated based on the normalized RGB values, the largest value (Max value), and the smallest value (Min value).

Specifically, if Max is the R value, the Hue value (H) can be determined by the following mathematical expression 1.

Here, H is the Hue value, G is the normalized G value, B is the normalized B value, Max is the largest value among the normalized RGB values, and Min can be the smallest value among the normalized RGB values.

Additionally, if Max is the G value, the Hue value (H) can be determined by the mathematical expression 2 below.

Here, H is the Hue value, B is the normalized B value, R is the normalized R value, Max is the largest value among the normalized RGB values, and Min can be the smallest value among the normalized RGB values.

Additionally, if Max is the B value, the Hue value (H) can be determined by the mathematical expression 3 below.

Here, H is the Hue value, R is the normalized R value, G is the normalized G value, Max is the largest value among the normalized RGB values, and Min can be the smallest value among the normalized RGB values.

After the Hue value is calculated using Equations 1 to 3, a step of correcting the calculated Hue value may be performed. If the calculated Hue value is negative, the Hue value may be corrected to have a positive value by adding 360 degrees.

By performing the above-described steps, the color tone values (Hue values) of 100 extracted fat samples can be derived.

Referring to FIG. 2, it can be confirmed that the numerical range of the hue values of 100 extracted fat samples is obtained from about 15 degrees to about 60 degrees. That is, the fat samples can implement a continuous color from an orange color corresponding to a hue value of about 15 degrees to a yellow color corresponding to a hue value of about 60 degrees.

That is, analysis of extracted fat samples revealed that human fat can have a color tone value ranging from approximately 15 degrees to approximately 60 degrees. In other words, if the color tone value is less than 15 degrees, it may be closer to a bright red, indicating a color somewhat distant from fat. If the color tone value exceeds 60 degrees, it may be closer to a bright green, indicating a color somewhat distant from fat.

Figure 3 is a diagram showing the wavelength of visible light corresponding to the color tone value.

In order for the dermal filler composition of the present disclosure to have a color tone value that is substantially the same as or similar to the color tone value of the extracted fat sample, a wavelength of visible light corresponding to a range of color tone values of 15 degrees to 60 degrees of the plurality of fat samples can be extracted.

Specifically, the wavelength of visible light reflected from the dermal filler composition may have different values based on the color of the dermal filler composition. Additionally, the value of the wavelength of visible light reflected from the dermal filler composition may be determined by the hue value of the dermal filler composition.

The method for obtaining the wavelength of visible light reflected by a dermal filler composition based on the hue value of the dermal filler composition can be performed by linear interpolation. However, the method is not limited to the above, and the wavelength of visible light can be obtained based on the hue value using various methods.

Referring to FIG. 3, it can be confirmed that the wavelength of visible light corresponding to the range of 15 to 60 degrees, which is the color tone value (Hue value) of 100 fat samples extracted from a human body, is about 570 nm (nanometers) to about 610 nm.

Through this, it can be explained that the skin filler composition implements a color similar to the color of fat when the wavelength of visible light reflected by the skin filler composition is 570 nm to 610 nm.

The present applicant conducted an experiment in which various weight ratios of carotenoids were added to a transparent hyaluronic acid filler composition based on color tone values obtained from fat samples, so that the dermal filler composition of the present disclosure reflects visible light of 570 nm to 610 nm and implements a color similar to the color of fat.

The dermal filler composition of the present disclosure may comprise about 3 μg to about 60 μg of a carotenoids per 1 g of the filler composition. The μg may be micrograms, and may be 0.000001 g. Additionally, the carotenoids may comprise β-carotene.

The dermal filler composition may comprise a carotenoids in a weight ratio of about 3 μg to about 60 μg per 1 g of the dermal filler composition, such that the dermal filler composition may reflect visible light of 570 nm to 610 nm to produce a color similar to the color of fat.

Specifically, when the dermal filler composition comprises about 3 μg of carotenoids per 1 g of the dermal filler composition, the dermal filler composition can absorb and reflect visible light of about 570 nm (e.g., visible light close to yellow).

Additionally, when the dermal filler composition comprises about 60 μg of carotenoids per 1 g of the dermal filler composition, the dermal filler composition can absorb and reflect visible light of about 610 nm (e.g., visible light close to orange).

That is, when the dermal filler composition contains less than 3 μg of carotenoids in a weight ratio per 1 g of the dermal filler composition, the dermal filler composition can reflect a color of visible light close to a transparent color that is somewhat distant from the color of fat due to the relatively small weight ratio of carotenoids.

Additionally, when the dermal filler composition comprises a weight ratio of more than 60 μg of carotenoids per 1 g of the dermal filler composition, the dermal filler composition may reflect a color of visible light close to red, which is somewhat distant from the color of fat, due to the relatively large weight ratio of carotenoids.

The dermal filler composition of the present disclosure can include a carotenoids in a weight ratio of about 3 μg to about 60 μg per 1 g of the dermal filler composition, so that the dermal filler composition can absorb and reflect visible light having a wavelength corresponding to 570 nm to 610 nm, which is the wavelength of visible light reflected by the fat sample described with reference to FIG. 1, and thus can implement a color similar to the color of fat.

The carotenoids contained in the dermal filler composition of the present disclosure are pigments characterized by a yellow or orange color. Carotenoids may include two types, such as carotene and xanthophylls. Carotene may be a pure hydrocarbon carotenoid that does not contain oxygen, and xanthophylls may be carotenoids that contain oxygen.

Additionally, the dermal filler composition of the present disclosure may include β-carotene, a carotenoid. Since β-carotene has a color similar to yellow or orange, the inclusion of β-carotene in the dermal filler composition of the present disclosure may allow the dermal filler composition to have a color similar to the color of fat.

Additionally, β-carotene has antioxidant properties and can be converted into vitamin A in the human body. As β-carotene is converted into vitamin A in the human body, its effects on vision protection, skin health, etc. may be reduced. Furthermore, since the dermal filler composition of the present disclosure includes β-carotene, the antioxidant effects of β-carotene can be further enhanced.

The benefits of β-carotene accumulating in subcutaneous fat are primarily related to its antioxidant properties. As a powerful antioxidant, β-carotene can help neutralize free radicals in the body. This protects subcutaneous fat from oxidative stress. Specifically, β-carotene's benefits for subcutaneous fat include:

[Antioxidant Protection] β-carotene can protect skin and subcutaneous fat cells from damage. It reduces oxidative damage caused by reactive oxygen species and UV rays, which may also contribute to anti-aging.

[Vitamin A precursor] β-carotene is converted into vitamin A as needed in the body, and vitamin A plays an important role in skin health. For example, it can help regenerate and protect skin and strengthen immune function.

[Improved Skin Tone] When β-carotene accumulates in subcutaneous fat, it can give your skin a natural tan tone. This can give your skin a healthier, more radiant appearance.

[UV protection] β-carotene can alleviate skin damage caused by UV rays.

Additionally, the dermal filler composition of the present disclosure can be formed of a first combination comprising at least one of β-carotene, α-carotene, lycopene, β-cryptoxanthin, lutein, zeaxanthin, saffron yellow, and alpha crocin.

In an exemplary embodiment, the dermal filler composition may include any one of β-carotene, α-carotene, lycopene, β-cryptoxanthin, lutein, zeaxanthin, saffron yellow, and alpha crocin.

However, without limitation thereto, the dermal filler composition may include two or more of β-carotene, α-carotene, lycopene, β-cryptoxanthin, lutein, zeaxanthin, saffron yellow, and alpha crocin.

The above β-carotene, α-carotene, lycopene, β-cryptoxanthin, lutein, zeaxanthin, saffron yellow, and alpha crocin may all be a type of carotenoids.

In an exemplary embodiment, α-carotene is a carotenoid that may have properties similar to β-carotene. α-carotene is yellow or orange in color, and some of it is converted to vitamin A in the human body, which can reduce oxidative damage to cells.

In an exemplary embodiment, lycopene is a yellow or orange-colored carotenoid that exhibits antioxidant properties. Accordingly, lycopene may have anticancer effects, positively impact cardiovascular health, and play a key role in cell protection and immune enhancement.

In an exemplary embodiment, β-cryptoxanthin is a yellow or orange carotenoid that protects cells through antioxidant activity, and some of which is converted to vitamin A in the body, which may help support bone health and immune function.

In an exemplary embodiment, lutein is a yellow or orange carotenoid that plays an important role in eye health and may help prevent macular degeneration.

In an exemplary embodiment, zeaxanthin is a yellow or orange carotenoid that may help protect vision by preventing light-induced damage.

In an exemplary embodiment, saffron yellow is a carotenoid extracted from saffron, which is primarily yellow or orange in color and has antioxidant and anti-inflammatory properties, which have positive effects on mood improvement and neuroprotection.

In an exemplary embodiment, alpha crocin is one of the main components extracted from saffron, has a yellow or orange color, and has antioxidant and anti-inflammatory properties, which may contribute to preventing cell damage and protecting nerves.

As described above, the dermal filler composition of the present disclosure can be formed of a first combination comprising at least one of β-carotene, α-carotene, lycopene, β-cryptoxanthin, lutein, zeaxanthin, saffron yellow, and alpha crocin.

Additionally, the weight ratio of the first combination may be about 3 μg to about 60 μg per 1 g of the filler composition. Since the aforementioned β-carotene, α-carotene, lycopene, β-cryptoxanthin, lutein, zeaxanthin, saffron yellow, and alpha crocin can all have a color close to yellow or orange, when the filler composition of the present disclosure includes about 3 μg to about 60 μg of the first combination per 1 g, the filler composition can implement a color similar to the color of fat.

In an exemplary embodiment, the dermal filler composition may further include hyaluronic acid (A), a cross-linking agent, a buffer, and lidocaine.

Hyaluronic acid, a component of dermal filler compositions, can play a role in retaining moisture and providing volume to skin tissue. Because hyaluronic acid attracts moisture, it can provide volume and hydration to the injected skin layer. Furthermore, cross-linked hyaluronic acid slows down the rate of decomposition, increasing the longevity of the filler.

In an exemplary embodiment, the hyaluronic acid may comprise a weight ratio of about 0.01 g to about 0.03 g per gram of the dermal filler composition. That is, the hyaluronic acid may comprise a weight ratio of about 10 mg to 30 mg per gram of the dermal filler composition. 1 mg may be 0.001 g.

In exemplary embodiments, a cross-linking agent may be used to enhance the durability and physical stability of dermal fillers. For example, BDDE (1,4-Butanediol diglycidyl ether) may be used as a cross-linking agent, forming bonds between hyaluronic acid molecules to prevent the hyaluronic acid from being easily degraded in the body. In other words, cross-linking agents can play a significant role in controlling the viscosity and elasticity of fillers and extending the product's shelf life.

In an exemplary embodiment, the crosslinking agent may be present in a weight ratio of 5 mg to 25 mg per gram of the filler composition. That is, the crosslinking agent may be present in a weight ratio of 0.005 g to 0.025 g per gram of the filler composition.

In exemplary embodiments, at least one of divinyl sulfone (DVS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), polyethylene glycol diglycidyl ether (PEGDE), Genipin, and a urethane crosslinker may be used in addition to the crosslinking agent mentioned above.

DVS is a cross-linking agent for hyaluronic acid, capable of forming a stable gel structure. By selecting DVS as a cross-linking agent, the dermal filler composition can form a solid gel.

Additionally, EDC can form amide bonds without adding additional molecular length to the hyaluronic acid chain. Furthermore, EDC may have excellent biocompatibility.

PEGDE can be used to create hydrogels, and genipin, a natural plant-derived cross-linker, may be more biocompatible than synthetic cross-linkers. Additionally, urethane-based cross-linkers can provide flexibility and stability to hyaluronic acid gels.

A buffer can serve as a buffer to control the pH of the filler and maintain its stability. The buffer can include phosphate-buffered saline (PBS). For example, the buffer can be composed of water and a buffer solution. Specifically, the buffer can be used to fill the remaining volume to reach the total amount of the dermal filler composition while adjusting other ingredients, such as hyaluronic acid, a cross-linker, and lidocaine.

The buffer can comprise a majority of the filler composition. Furthermore, the buffer can regulate the chemical environment of the filler, ensuring that the hyaluronic acid-containing filler remains safe and stable.

In an exemplary embodiment, the buffer may comprise the remaining proportion excluding the hyaluronic acid, cross-linking agent, and lidocaine. For example, the buffer may comprise a weight ratio of about 950 mg to 985 mg per gram of the filler composition. That is, the buffer may comprise a weight ratio of about 0.950 g to about 0.985 g per gram of the filler composition.

The hyaluronic acid, cross-linking agent, and buffer described above may all be colorless, transparent substances.

In the dermal filler composition of the present disclosure, the weight ratio of the carotenoids is 3 μg to 60 μg per 1 g of the dermal filler composition, the weight ratio of the hyaluronic acid is 0.01 g to 0.03 g per 1 g of the dermal filler composition, the weight ratio of the cross-linking agent is 5 mg to 25 mg per 1 g of the dermal filler composition, and the buffer can occupy the remaining weight ratio excluding the carotenoids, the hyaluronic acid, and the cross-linking agent, so that the dermal filler composition of the present disclosure can have a color similar to that of fat, can improve the Tyndall phenomenon, and can help in tissue repair and regeneration of a skin layer into which the filler is injected.

Lidocaine is a local anesthetic that can reduce pain during filler injection. Lidocaine may be optionally included in the composition of the filler composition. That is, the dermal filler composition of the present disclosure may not include lidocaine.

When the filler composition of the present disclosure includes lidocaine, the lidocaine may occupy a weight ratio of about 2 mg to about 4 mg per 1 g of the filler composition.

As described above, the dermal filler composition of the present disclosure can include a weight ratio of about 3 μg to about 60 μg of a carotenoids (e.g., β-carotene) per 1 g of the dermal filler composition, such that the dermal filler composition can have a color similar to the color of fat.

To further verify whether the dermal filler composition comprising a carotenoids (e.g., β-carotene) in a weight ratio of about 3 μg to about 60 μg per 1 g of the dermal filler composition of the present disclosure implements a color similar to the color of human fat, dermal filler compositions containing carotenoids in various weight ratios were prepared, and the following questionnaire was administered to 20 doctors specializing in liposuction and transplantation.

Specifically, 16 dermal filler composition samples were prepared, each containing carotenoids in weight ratios of 0 μg, 1 μg, 2 μg, 3 μg, 4 μg, 5 μg, 10 μg, 20 μg, 30 μg, 40 μg, 50 μg, 60 μg, 61 μg, 62 μg, 70 μg, and 80 μg per 1 g of the dermal filler composition.

Additionally, the applicant asked 20 physicians specializing in liposuction and liposuction to rate the degree to which the 16 dermal filler composition samples resembled the color of purified pure fat for fat grafting.

Specifically, the applicant asked 20 doctors to give a score closer to 10 as the color was closer to the color of purified pure fat, and to give a score closer to 0 as the color was farther from the color of purified pure fat.

The results of the evaluation by 20 doctors are shown in Table 1 below. The local color similarity was calculated as the average of the 20 doctors.

Carotenoids ratio
μg per 1g of weight 0
μg 1
μg 2
μg 3
μg 4
μg 5
μg 10
μg 20
μg 30
μg 40
μg 50
μg 60
μg 61
μg 62
μg 70
μg 80
μg Local color similarity 0 2.4 3.2 9.2 9.3 9.4 9.4 9.4 9.3 9.4 9.3 9.4 6.2 5.2 4.2 2.1

Based on the aforementioned Table 1, it can be confirmed that when the dermal filler composition has a weight ratio of 0 μg, 1 μg, and 2 μg of carotenoids per 1 g of the dermal filler composition, the lipocolor similarity scores are low, at 0, 2.4, and 3.2 points, respectively.

In addition, when the dermal filler composition has a weight ratio of carotenoids of 61 μg, 62 μg, 70 μg, and 80 μg per 1 g of the dermal filler composition, respectively, it can be confirmed that the lipocolor similarity scores are low, 6.2 points, 5.2 points, 4.2 points, and 2.1 points, respectively.

In addition, when the dermal filler composition has carotenoids in weight ratios of 3 μg, 4 μg, 5 μg, 10 μg, 20 μg, 30 μg, 40 μg, 50 μg, and 60 μg per 1 g of the dermal filler composition, it can be confirmed that the lipocolor similarity scores are high, 9.2, 9.3, 9.4, 9.4, 9.4, 9.3, 9.4, 9.3, and 9.4, respectively.

That is, referring to Table 1 described above, when the dermal filler composition of the present disclosure includes a carotenoids in a weight ratio of 3 μg per 1 g, it can be confirmed that the color of the dermal filler composition of the present disclosure is very similar to the color of fat, starting from the weight ratio of 3 μg.

Additionally, referring to Table 1 described above, when the dermal filler composition of the present disclosure comprises a carotenoids at a weight ratio of 60 μg per 1 g, it can be confirmed that the color of the dermal filler composition of the present disclosure is very similar to the color of fat with the weight ratio of 60 μg as the endpoint.

Referring to Table 1 mentioned above, it can be confirmed that the local color similarity score is 9.2 at 3 μg and then sharply decreases to 3.2 at 2 μg. Also, referring to Table 1 mentioned above, it can be confirmed that the local color similarity score is 9.4 at 60 μg and then sharply decreases to 6.2 at 61 μg.

That is, when the dermal filler composition of the present disclosure comprises a carotenoids having a weight ratio of about 3 μg to about 60 μg per 1 g of the filler composition, the conclusion that the color of the dermal filler composition of the present disclosure is very similar to the color of purified pure fat can be obtained from the results of a questionnaire of doctors specializing in liposuction and transplantation.

That is, the dermal filler composition of the present disclosure can be proven to have a critical significance in a numerical range of carotenoids in a weight ratio of about 3 μg to about 60 μg per 1 g of the filler composition as a result of a physician's questionnaire.

In addition, it is confirmed that the results of the questionnaire of the present physician shown in Table 1 above are consistent with the values determined by the applicant by extracting 100 fat samples and determining the weight ratio range (i.e., numerical range) of carotenoids to match the color of the fat samples.

As described above, exemplary embodiments have been disclosed in the drawings and specifications. While specific terminology has been used to describe embodiments herein, it is intended solely to illustrate the technical concept of the present disclosure and is not intended to limit the scope of the present disclosure as defined in the claims. Therefore, those skilled in the art will appreciate that various modifications and equivalent embodiments are possible. Therefore, the true technical protection scope of the present disclosure should be determined by the technical concept of the appended claims.

Claims (11)

A dermal filler composition comprising a carotenoid to be inserted into a skin layer to implement a fat color, wherein the weight ratio of the carotenoid is 3 μg to 60 μg per 1 g of the dermal filler composition so as to implement a color tone value of 15 to 60 degrees. In the first paragraph,
The above carotenoids are,
A skin filler composition characterized by being β-carotene. delete In the first paragraph,
The above carotenoids are,
A dermal filler composition characterized by being formed of a first combination comprising at least one of β-carotene, α-carotene, lycopene, β-cryptoxanthin, lutein, zeaxanthin, saffron yellow, and alpha crocin. In the fourth paragraph,
A skin filler composition, characterized in that the weight ratio of the first combination is 3 μg to 60 μg per 1 g of the skin filler composition. In the first paragraph,
The above skin filler composition,
A dermal filler composition further comprising hyaluronic acid, a cross-linking agent, and a buffer. In paragraph 6,
The above skin filler composition,
A dermal filler composition characterized by further comprising lidocaine. In paragraph 6,
In the above skin filler composition,
The hyaluronic acid comprises a weight ratio of 0.01 g to 0.03 g per 1 g of the dermal filler composition,
The crosslinking agent occupies a weight ratio of 0.005 g to 0.025 g per 1 g of the dermal filler composition,
A dermal filler composition characterized in that the buffer occupies the remaining weight ratio excluding the carotenoids, the hyaluronic acid, and the crosslinking agent. In the first paragraph,
The wavelength of visible light reflected by the above filler composition is
A dermal filler composition characterized by having a wavelength of 570 nm to 610 nm. delete In the first paragraph,
The above filler composition,
A dermal filler composition characterized in that it is injected into the forehead, under the eyes, and bridge of the nose among the skin layers of the human body.